Pharmacological inhibition of poly(ADP-ribose) polymerase inhibits angiogenesis
Pharmacological inhibition of poly(ADP-ribose) polymerase inhibits angiogenesis
复制标题
DOI：
10.1016/j.bbrc.2006.09.049
复制
发表时间：
2006-11-17
影响因子：
3.1
通讯作者：
Pacher, Pal
中科院分区：
文献类型：
--
作者：
Rajesh, Mohanraj;Mukhopadhyay, Partha;Pacher, Pal
多聚腺苷二磷酸核糖聚合酶（Poly（ADP-ribose）polymerase，PARP）是一种在调节细胞死亡和DNA修复反应中起重要作用的核酶。PARP的药理学抑制剂被认为是治疗癌症的单一疗法以及与化疗剂和放射的组合，并且还报告了对某些抗癌药物产生的不良作用的保护作用。在这里，我们表明，3-氨基苯甲酰胺或PJ-34的药理学抑制PARP剂量依赖性地减少VEGF诱导的增殖，迁移和管形成的人脐静脉内皮细胞在体外。这些结果表明，用PARP抑制剂治疗可以通过减少血管生成在各种癌症和视网膜病中发挥额外的益处。(c)2006年爱思唯尔公司All rights reserved.
Poly(ADP-ribose) polymerase (PARP) is a nuclear enzyme which plays an important role in regulating cell death and cellular responses to DNA repair. Pharmacological inhibitors of PARP are being considered as treatment for cancer both in monotherapy as well as in combination with chemotherapeutic agents and radiation, and were also reported to be protective against untoward effects exerted by certain anticancer drugs. Here we show that pharmacological inhibition of PARP with 3-aminobenzamide or PJ-34 dose-dependently reduces VEGF-induced proliferation, migration, and tube formation of human umbilical vein endothelial cells in vitro. These results suggest that treatment with PARP inhibitors may exert additional benefits in various cancers and retinopathies by decreasing angiogenesis. (c) 2006 Elsevier Inc. All rights reserved.